| 著者名 | 標題 | 誌名 |
|---|---|---|
| Shiota M, Tsukahara S, Takamatsu D, Tanegashima T, Ueda S, Blas L, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Shioyama Y, Eto M: | Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate. | Asian J Endosc Surg 17 (1): e13279, 2024 |
| Kiyozawa D, Kohashi K, Takamatsu D, Umekita S, Eto M, Kinjo M, Nishiyama K, Taguchi K, Oshiro Y, Kuboyama Y, Oda Y: | Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma. | J Clin Pathol 77 (2): 105-110, 2024 |
| Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M: | Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab. | Clin Genitourin Cancer 22 (1): e122-e127.e1., 2024 |
| Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H: | Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). | Int J Urol 31 (3): 265-272, 2024 |
| Nagakawa S, Shiota M, Takamatsu D, Tsukahara S, Mastumoto T, Blas L, Inokuchi J, Oda Y, Eto M: | Clinical features and oncological outcomes of bladder cancer microsatellite instability. | Int J Urol 31 (4): 438-445, 2024 |
| Blas L, Shiota M, Tanegashima T, Tsukahara S, Ueda S, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Eto M: | Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy. | Int J Urol 31 (4): 404-408, 2024 |
| Ota M, Oki E, Nakanoko T, Tanaka Y, Toyota S, Hu Q, Nakaji Y, Nakanishi R, Ando K, Kimura Y, Hisamatsu Y, Mimori K, Takahashi Y, Morohashi H, Kanno T, Tadano K, Kawashima K, Takano H, Ebihara Y, Shiota M, Inokuchi J, Eto M, Yoshizumi T, Hakamada K, Hirano S, Mori M: | Field experiment of a telesurgery system using a surgical robot with haptic feedback. | Surg Today 54 (4): 375-381, 2024 |
| Kashiwagi E, Kawahara T, Kinoshita F, Shiota M, Inokuchi J, Miyamoto H, Eto M: | The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression. | Anticancer Res 44 (4): 1369-1376, 2024 |
| Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N: | Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project. | BJC Rep 2 (1): 28, 2024 |
| Nishiyama H, Yonese J, Kawahara T, Matsumoto R, Miyake H, Matsubara N, Uemura H, Eto M, Azuma H, Obara W, Terai A, Fukasawa S, Suekane S: | TAS0313 Plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma. | Mol Cancer Ther 23 (4): 532-540, 2024 |
| Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators: | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. | J Clin Oncol 42 (11): 1222-1228, 2024 |
| Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S: | GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401. | Int J Urol 31 (4): 362-369, 2024 |
| Nakanishi S, Fukushima Y, Inokuchi J, Hakariya T, Kakinoki H, Enokida H, Chikui K, Matsuoka H, Shin T, Mukai S, Kamba T, Eto M, Imamura R, Noguchi M, Igawa T, Haga N, Kamoto T, Fujimoto N, Saito S: | Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan. | Int J Urol 31 (5): 484-491, 2024 |
| Fukumoto T, Umakoshi H, Iwahashi N, Ogasawara T, Yokomoto-Umakoshi M, Kaneko H, Fujita M, Uchida N, Nakao H, Kawamura N, Matsuda Y, Sakamoto R, Miyazawa T, Seki M, Eto M, Oda Y, Suzuki Y, Ogawa S, Ogawa Y: | Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma. | EBioMedicine 103: 105087, 2024 |
| Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group: | Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. | Ann Surg Oncol 31 (6): 3872-3879, 2024 |
| Kato M, Shiota M, Kimura T, Hanazawa R, Hirakawa A, Takamatsu D, Tashiro K, Matsui Y, Hashine K, Saito R, Yokomizo A, Yamamoto Y, Narita S, Hashimoto K, Matsumoto H, Akamatsu S, Nishiyama N, Eto M, Kitamura H, Tsuzuki T; Japanese Urological Oncology Group: | Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort. | Int J Urol 31 (6): 662-669, 2024 |
| Blas L, Shiota M, Tanegashima T, Kobayashi S, Matsumoto T, Eto M: | Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer. | Int J Urol 31 (7): 829-831, 2024 |
| Yokoyama M, Chen W, Waseda Y, Fujiwara M, Kato D, Shirakawa T, Shimizu Y, Nenohi T, Matsumoto Y, Okumura T, Urushibara M, Ai M, Fushimi K, Fukagai T, Eto M, Fujii Y, Ishizaka K: | Comparisons of in-hospital fee and surgical outcomes between robot-assisted, laparoscopic, and open radical cystectomy: a Japanese nationwide study. | Jpn J Clin Oncol 54 (7): 822-826, 2024 |
| Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T: | Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. | Eur Urol 86 (1): 4-9, 2024 |
| Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M: | Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study. | J Immunol 213 (1): 23-28, 2024 |
| Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Tanegashima T, Eto M: | Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer. | Int J Urol 31 (8): 945-947, 2024 |
| Kobayashi S, Tsukino K, Mutaguchi J, Tanegashi T, Goto S, Matsumoto T, Shiota M, Eto M: | Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis. | J Robot Surg 18 (1): 314, 2024 |
| Kiyozawa D, Iwasaki T, Takamatsu D, Kohashi K, Miyamoto T, Fukuchi G, Eto M, Yamashita M, Oda Y: | Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y. | Virchows Arch 485 (2): 299-306, 2024 |
| Mori M, Hirano S, Hakamada K, Oki E, Urushidani S, Uyama I, Eto M, Ebihara Y, Kawashima K, Kanno T, Kitsuregawa M, Kinugasa Y, Kobayashi J, Nakamura H, Noshiro H, Mandai M, Morohashi H: | Clinical practice guidelines for telesurgery 2022 : Committee for the promotion of remote surgery implementation, Japan Surgical Society. | Surg Today 54 (8): 817-828, 2024 |
| Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Okada T, Tanegashima T, Kobayashi S, Matsumoto T, Eto M: | Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer. | Free Radic Biol Med 221: 81-88, 2024 |
| Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N: | Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project. | World J Urol 42 (1): 526, 2024 |
| Fujimoto N, Nagata Y, Shiota M, Minato A, Tomisaki I, Harada K, Eto M, Miyamoto H: | The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer. | In Vivo 38 (5): 2328-2334, 2024 |
| Shiota M, Nemoto S, Ikegami R, Tatarano S, Kamoto T, Kobayashi K, Sakai H, Igawa T, Kamba T, Fujimoto N, Yokomizo A, Naito S, Eto M: | Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A study. | BJC Rep 2 (1): 69, 2024 |
| Tanegashima T, Shiota M, Kimura T, Takamatsu D, Matsui Y, Yokomizo A, Saito R, Morizane S, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Edamura K, Narita S, Yamaguchi T, Kasahara T, Hashimoto K, Kato M, Yoshino T, Akamatsu S, Matsukawa A, Kaneko T, Matsumoto R, Joraku A, Kato M, Saito T, Kato T, Tatarano S, Sakamoto S, Kanno H, Terada N, Nishiyama N, Kitamura H, Eto M; Japanese Urological Oncology Group: | Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement. | Int J Clin Oncol 29 (10): 1586-1593, 2024 |
| Tanegashima T, Shiota M, Tsukahara S, Mutaguch J, Goto S, Kobayashi S, Matsumoto T, Eto M: | Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients. | Prostate 84 (14): 1329-1335, 2024 |
| Blas L, Shiota M, Matsuyama H, Kamoto T, Enokida H, Fujimoto N, Sakai H, Igawa T, Kamba T, Yokomizo A, Naito S, Eto M: | Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer. | World J Urol 42 (1): 604, 2024 |
| Hinata N, Murakami S, Nakano Y, Hara I, Kondo T, Hamamoto S, Shiroki R, Nagayama J, Kawakita M, Eto M, Ukimura O, Takenaka A, Takagi T, Shimbo M, Azuma H, Yoshida T, Furukawa J, Kawamorita N, Fujisawa M: | Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study. | Int J Clin Oncol 29 (10): 1548-1556, 2024 |
| Yasui T, Kikuchi E, Yamamoto H, Ishii D, Mizuno R, Hatakeyama S, Kobayashi T, Uchida J, Takahashi M, Sakamoto S, Morizane S, Kamoto T, Eto M: | Annual record on the number of general urological surgeries registered in the National Clinical Database system between April 2018 and December 2021 in Japan. | Int J Urol 31 (11): 1256-1262, 2024 |
| Shiota M, Shimbo M, Tsukahara S, Tanegashima T, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Hattori K, Endo F, Eto M: | Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer. | Ann Surg Oncol 31 (13): 8986-8992, 2024 |
| Kikuchi E, Yamamoto H, Yasui T, Hatakeyama S, Mizuno R, Sakamoto S, Mizuno K, Morizane S, Hayakawa N, Kobayashi T, Kamoto T, Eto M: | The first detailed annual record on the National Clinical Database Urology Division in Japan: A report on five surgical procedures. | Int J Urol 31 (12): 1344-1355, 2024 |
| Fukushima T, Goto K, Hayashi T, Ikeda K, Hatayama T, Yamanaka R, Iwane K, Tasaka R, Kohada Y, Takemoto K, Kobatake K, Goriki A, Toshida A, Nakahara H, Motonaga M, Tokumo K, Fujii Y, Hayes CN, Okamoto W, Kubo T, Matsumoto T, Shiota M, Yamamoto N, Urabe Y, Hiyama E, Arihiro K, Hinoi T, Hinata N: | Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study. | Jpn J Clin Oncol 54 (2): 175-181, 2024 |
| Kikuchi H, Abe T, Miyake M, Miyata H, Matsumoto R, Osawa T, Nishimura N, Fujimoto K, Inokuchi J, Yoneyama T, Tomida R, Numakura K, Matsushita Y, Matsumoto K, Sato T, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Shinohara N: | The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy. | Jpn J Clin Oncol 54 (2): 192-200, 2024 |
| Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Okajima E, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K: | Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis. | World J Urol 42 (1): 185, 2024 |
| Sakamoto S, Sato K, Kimura T, Matsui Y, Shiraishi Y, Hashimoto K, Miyake H, Narita S, Miki J, Matsumoto R, Kato T, Saito T, Tomida R, Shiota M, Joraku A, Terada N, Suekane S, Kaneko T, Tatarano S, Yoshio Y, Yoshino T, Nishiyama N, Kawakami E, Ichikawa T, Kitamura H: | PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer. | Sci Rep. 2024 14 (1): 15307, 2024 |
| Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y; Japanese Urological Oncology Group: | Prognostic impact of histological discordance between transurethral resection and radical cystectomy. | BJU Int 134 (2): 207-218, 2024 |
| Kawai T, Onozawa M, Taguchi S, Shiota M, Sakamoto S, Yamamoto Y, Kitagawa Y, Nakagawa T, Hinotsu S, Kume H; Japan Study Group of Prostate Cancer (J-CaP): | Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study. | Jpn J Clin Oncol 54 (9): 1045-1051, 2024 |
| Kudo Y, Nakamura K, Tsuzuki H, Hirota K, Kawai M, Takaya D, Fukuzawa K, Honma T, Yoshino Y, Nakamura M, Shiota M, Fujimoto N, Ikari A, Endo S: | Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition. | Arch Biochem Biophys 760: 110135, 2024 |
| Kato T, Matsumoto R, Yokomizo A, Tohi Y, Fukuhara H, Fujii Y, Mori K, Sato T, Inokuchi J, Hashine K, Sakamoto S, Kinoshita H, Inoue K, Tanikawa T, Utsumi T, Goto T, Hara I, Okuno H, Kakehi Y, Sugimoto M: | Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN). | BJU Int 134 (4): 652-658, 2024 |
| Kato M, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Yamamoto S, Matsue T, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Uchida J; Japan Urological Oncology Group: | Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study. | Int J Clin Oncol 29 (12): 1937-1945, 2024 |